A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial.

AJ, Lansky; J, Schofer; D, Tchetche; P, Stella; CG, Pietras; H, Parise; K, Abrams; JK, Forrest; M, Cleman; J, Reinöhl; T, Cuisset; D, Blackman; G, Bolotin; S, Spitzer; U, Kappert; M, Gilard; T, Modine; D, Hildick-Smith; M, Haude; P, Margolis; AM, Brickman; S, Voros; A, Baumbach

doi:10.1093/eurheartj/ehv191

Public

A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial.

Shared by NobleBlocks on May 19, 2015 • 12:00 AM UTC

Authors:

Lansky AJ

Schofer J

Tchetche D

Abstract

Aims To evaluate the safety, efficacy, and performance of the TriGuard™ HDH Embolic Deflection Device (TriGuard) compared with no cerebral protection in patients undergoing transcatheter aortic valve implantation (TAVI).Methods and results From February 2014 to March 2015, 85 subjects undergoing TAV...

Subject

neuroprotection

Cerebral Ischaemia

Diffusion-weighted Imaging

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!